KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
82 hedge funds and large institutions have $303M invested in KalVista Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 22 increasing their positions, 24 reducing their positions, and 4 closing their positions.
475% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 4
49% more capital invested
Capital invested by funds: $203M → $303M (+$99.6M)
30% more funds holding
Funds holding: 63 → 82 (+19)
0.88% more ownership
Funds ownership: 90.46% → 91.33% (+0.88%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
8% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 24
16% less call options, than puts
Call options by funds: $5.6M | Put options by funds: $6.68M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.41M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$3.26M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$2.84M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
+$2.43M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.94M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$2.62M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$2.57M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.74M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.71M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
| $5K | +$4.77K | +278 | New |
|
77
Group One Trading
Chicago,
Illinois
| $4K | +$3.57K | +208 | New |
|
|
VFA
78
Valeo Financial Advisors
Carmel,
Indiana
| $3K | – | – | – |
|
|
SB
79
Samsara BioCapital
Palo Alto,
California
| $1.28K | -$288K | -16,817 | -20% |
|
|
QCG
80
Quadrant Capital Group
Cincinnati,
Ohio
| $1K | – | – | – |
|
81
Daiwa Securities Group
Tokyo,
Japan
| $1K | +$583 | +34 | New |
|
|
AIG
82
American International Group
New York
| $161 | +$5.69K | +332 | +4% |
|
|
DCM
83
DAFNA Capital Management
Los Angeles,
California
| – | -$2.62M | -208,054 | Closed |
|
|
AA
84
ALPS Advisors
Denver,
Colorado
| – | -$287K | -22,822 | Closed |
|
85
Norges Bank
Oslo,
Norway
| – | -$269K | -21,400 | Closed |
|
|
WG
86
Winton Group
London,
United Kingdom
| – | -$194K | -15,427 | Closed |
|
KALV Hedge Fund Activity: Q4 2020 in Review
82 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2020, worth a combined $303M — up 49% from $203M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new KALV positions and 4 closed out — a net gain of 19 holders — while 22 added to existing stakes and 24 trimmed.
The largest buyer was BlackRock, adding an estimated $3.41M. The largest seller was Ikarian Capital, cutting an estimated $2.94M.
- 82 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2020, up from 63 in Q3 2020.
- Funds reported $303M of KalVista Pharmaceuticals stock for Q4 2020, up 49% quarter-over-quarter.
- 23 funds opened new KalVista Pharmaceuticals positions in Q4 2020 and 4 closed out, a net change of +19 holders.
- The largest KalVista Pharmaceuticals buyer in Q4 2020 was BlackRock, an estimated $3.41M added.
- The largest KalVista Pharmaceuticals seller in Q4 2020 was Ikarian Capital, an estimated $2.94M sold.
Based on aggregated 13F filings for Q4 2020.